88 results about "Coeliac disease" patented technology

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

A method for diagnosing and treating an immune microbial dysfunction in a subject, the method comprising: receiving an aggregate set of biological samples from a population of subjects; generating at least one of a microbiome composition dataset and a microbiome functional diversity dataset for the population of subjects; generating a characterization of the immune microbial dysfunction based upon features extracted from at least one of the microbiome composition dataset and the microbiome functional diversity dataset, wherein the characterization is diagnostic of at least one of Crohn's disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, and celiac disease; based upon the characterization, generating a therapy model configured to correct the immune microbial dysfunction; and at an output device associated with the subject, promoting a therapy to the subject based upon the characterization and the therapy model.

The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue. Analogs of such oligopeptides are useful in the inhibition of immune responses.

The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis.

Disclosed are glutamine endopeptidase enzymes from Rothia sp. bacteria that are naturally associated with the oral cavity, formulations comprising the glutamine endopeptidase enzymes and the use thereof for the treatment, prevention of allergic reaction and diagnosis of gluten allergy related diseases such as Celiac Sprue, gluten allergy and/or dermatitis herpetiformis.

A method for screening wheat varieties with low celiac sprue toxicity based on T cell epitopes comprises the following steps: separating and extracting wheat gluten protein in two steps, performing SDS-PAGE electrophoresis combined with PageBlue TM staining method to identify the gluten protein, detecting celiac sprue T cell epitopes caused by the gluten protein through immunoblotting and other steps. According to the invention, T cell epitopes-based screening method is adopted to screen out the wheat varieties with low celiac sprue toxicity, so that safe and reliable low gluten food can be supplied for celiac sprue patients from the origin of raw materials, and the safety risk of the celiac sprue patients is reduced.

The invention relates to a method for extracting the gluten contained in a sample using an ethanol aqueous solution in the presence of a composition containing a disulphur group reducer and a decoupling agent, in a buffer having a pH of between 7 and 8. The inventive method can be used to extract quantitatively the gluten contained in a heat-processed or non-heat processed food sample before the quantification of the gluten by ELISA. The method is suitable for food analyses, in particular, for foodstuffs intended for celiac sufferers.

The present invention relates to the field of medicine and in particular to celiac disease (CD). Specifically the present invention relates to methods and means for detection of CD using novel microbiomarker, celiac gut index (CGI). The invention relates also to methods and means for treatment or prophylaxis of CD. The present invention provides a novel product comprising a gut microbiome altering agent that, when administered to an individual, improves the state of health of individuals suffering or susceptible to suffer from celiac disease and possibly reduces the likelihood of acquiring celiac disease. The product of the invention provides a natural and safe manner for the treatment of celiac disease. The present invention provides also a novel method for aiding diagnosis of CD by the specific gut health biomarker, Celiac Gut Index (GCI). In the method a probability of a subject having celiac disease is determined by measuring the relative abundances of one or more microbial taxa in a fecal sample from a subject; and the probability of the subject having CD is determined based on the measured abundances as celiac gut index (CGI).

Patient reported outcome (PRO) instruments are useful for collecting information from celiac disease patients, patients with gluten intolerance or gluten sensitivity, and patients on gluten free diets.